Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
Date:11/15/2012

ption," added Mr. Bacha.

About VAL-083
VAL-083 represents a 'first in class' small-molecule chemotherapeutic. VAL-083 has been assessed in multiple NCI-sponsored clinical studies in various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer

Based on published research, the mechanism of action of VAL-083 is understood to be a bi-functional alkylating agent; however, the functional groups associated with alkylating events has been shown to differ from other alkylating agents used in the treatment of GBM.

VAL-083 has previously demonstrated activity in cyclophosphamide, BCNU and phenylanine mustard resistant cell lines and no evidence of cross-resistance has been encountered in published clinical studies.  Based on the presumed alkylating functionality of VAL-083, published literature suggests that DNA repair mechanisms associated with Temodar and nitrosourea resistance, such as 06-methylguanine methyltransferace (MGMT), may not confer resistance to VAL-083. 

VAL-083 readily crosses the blood brain barrier where it maintains a long half-life in comparison to the plasma.  Published preclinical and clinical research demonstrates that VAL-083 is selective for brain tumor tissue.

VAL-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors.  In general, tumor regression was achieved following therapy in greater than 40% of patients treated and stabilization was achieved in an additional 20% - 30%.  In published clinical studies, VAL-083 has previously been shown to have a statistically significant impact on median survival in high grade gliomas when combined with radiation vs. radiation
'/>"/>

SOURCE Del Mar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auspex Pharmaceuticals Receives U.S. Patent on Novel JAK Inhibitor SD-900
2. Access Pharmaceuticals To Host Third Quarter Investor Call on Wednesday, November 28th
3. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
4. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
5. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
8. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
9. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
10. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
11. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo Therapeutics, ... device company focused on skin permeation, continuous glucose ... Scott W. Hollander has been appointed Chief ... has more than 20 years of experience in ... and most recently served as Vice President, Business ...
(Date:12/24/2014)... Dec. 23, 2014   Assurex Health, a ... to healthcare providers for behavioral health and chronic ... $30 million in equity financing from new and ... , President and Chief Executive Officer. ... development of Assurex Health,s GeneSight ® ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Drug Safety Strategies and Risk ... clinical success ...
... FRANCISCO, Calif., Oct. 26, 2011 Onyx Pharmaceuticals, ... results from a Bayer HealthCare Pharmaceuticals Phase 3 ... for the treatment of patients with metastatic colorectal ... standard therapies. The trial met its primary endpoint ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 2Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 3Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 4Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 5
(Date:12/26/2014)... “Many people become overwhelmed by the ... issues and phone calls with insurance companies,” The Jones ... their free eBook on pedestrian and bicycle accidents ... and bicycle auto accident claims assures the injured individual ... professionally handling their case while they focus on recovering. ...
(Date:12/26/2014)... 26, 2014 Parker & Sons, ... best in heating, cooling and plumbing contractor services ... emergency services in 2014 with regard to air-conditioning ... Arizona is known for its incredibly hot summers. ... the intricacies and details of a wide variety ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
(Date:12/25/2014)... December 25, 2014 BambooFlooringChina.com sells many ... quality bamboo flooring. Today, the company announces big ... many styles and colors. , BambooFlooringChina.com is the world’s ... the promotion is valid until Jan. 20, 2015. , ... and woven with a natural thread. All the bamboo ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... ( Drosophila melanogaster ) males -- in which the activity ... -- show impairments in learning and memory as they age. ... deficits by treating the flies with drugs such as lithium, ... The research team -- Thomas A. Jongens, Ph.D., associate professor ...
... -- NewYork-Presbyterian Hospital, one of the country,s largest and most ... and #1 among ranked hospitals in the New York area, ... marks the 10th consecutive year that NewYork-Presbyterian has been listed ... Best Hospitals 2010-11 ranks 152 medical centers nationwide ...
... , THURSDAY, July 15 (HealthDay News) -- A study of ... than the recommended two hours of television a day. ... country," said study co-author Dr. John Oh, an epidemic intelligence ... and Prevention, working with Oregon Public Health. Experts have ...
... THURSDAY, July 15 (HealthDay News) -- For an hour after ... stroke increases, a small, preliminary study suggests. But even ... researchers noted that moderate drinking over the long-term might actually ... risk of ischemic stroke may be transiently elevated in the ...
... The Robert Wood Johnson Foundation, the nation,s largest philanthropy ... of all Americans, has chosen Dr. Paul Lipkin, Director ... for a highly coveted National Health Policy Fellowship. ... dramatic change, and the lives of millions are impacted ...
... of scientists, led by researchers at the University of California, ... responsible for a condition in which eye and brain development ... a potential remedy that would involve a simple, daily dietary ... disorders of glycosylation or CDG, a group of syndromes in ...
Cached Medicine News:Health News:Rescuing fruit flies from Alzheimer's disease 2Health News:Rescuing fruit flies from Alzheimer's disease 3Health News:Rescuing fruit flies from Alzheimer's disease 4Health News:NewYork-Presbyterian No. 6 hospital in nation, No. 1 in NY 2Health News:NewYork-Presbyterian No. 6 hospital in nation, No. 1 in NY 3Health News:Too Many Tots Watching Too Much TV: Study 2Health News:Too Many Tots Watching Too Much TV: Study 3Health News: Stroke Risk May Rise First Hour After Drinking 2Health News: Stroke Risk May Rise First Hour After Drinking 3Health News:Kennedy Krieger Institute's Dr. Paul Lipkin selected for national health policy fellowship 2Health News:UC San Diego researchers find cause of metabolic disease -- and possible cure 2Health News:UC San Diego researchers find cause of metabolic disease -- and possible cure 3
... This programmable system automates the denaturation ... procedures, and provides walk-away convenience for ... cost unit accepts a wide range ... use, and reduces hands-on time by ...
... bucket rotor. ,The MicroPrep 2 is a ... bucket rotor and optional fixed angle rotor.,The ... of clinical, biomedical, industrial, and biotechnology applications. ... "swinging bucket centrifuge in a small, low ...
... StatSpin MP is a small, quiet, high-speed ... and suspension system which results in nearly ... rotors achieve both top speed and full ... easily be changed with a simple push-on/ ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Medicine Products: